Geng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Geng Li has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Zehuai Wen
Guangdong Provincial Hospital of Chinese Medicine (Second Affiliated Hospital of Guangzhou University of Chinese Medicine) Guangdong Provincial Academy of Chinese Medical Sciences Guangzhou China
7 shared publications Jun Tan
Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
2 shared publications- Li Zhou
State Key Laboratory of Dampness Syndrome of Chinese Medicine, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
2 shared publications Ting Cheng
Second Clinical College of Guangzhou University of Chinese Medicine Guangzhou China
2 shared publications- Wencong Cao
Second Clinical Medical College (Second Affiliated Hospital), Guangzhou University of Chinese Medicine
2 shared publications - Wenwei Ouyang
Department of Methodology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
2 shared publications
Latest Publications
- 21 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70857
Association of Oxidative Balance Score and All‐Cause and Cardiovascular Mortality in Patients With Hyperuricemia and Gout: NHANES 1999–2018
- 21 September 2026
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 29 (9) , e70857
Association of Oxidative Balance Score and All‐Cause and Cardiovascular Mortality in Patients With Hyperuricemia and Gout: NHANES 1999–2018
- Open Access
- 30 June 2026
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 19 (2) , e70156
Development and Preliminary Validation of the Chinese Medicine Interventional Clinical Trials Research Question Importance Tool (CMICT‐RQIT)
Objective: Evidence‐based medicine emphasizes clinical research driven by important questions, yet Chinese medicine lacks practical quantitative tools to identify such questions. We developed the Chinese Medicine Interventional Clinical Trials Research Question Importance Tool (CMICT‐RQIT) to support topic selection and provide transparent criteria for proposal review, promoting high‐quality clinical research in Chinese medicine. Methods: This study followed internationally accepted procedures of conceptualization and operationalization. Using a mixed‐methods approach—including a literature review, qualitative interviews, Delphi surveys, expert consensus meetings, and the analytic hierarchy process—we developed the CMICT‐RQIT. CMICT‐RQIT was prespecified and interpreted as a formative/composite multicriteria decision‐support tool. Results: Following a standardized development process comprising three stages—framework construction, tool development, and tool evaluation—the CMICT‐RQIT V1.0 was established. It consists of four domains, 10 facets, and 24 items, each with corresponding composite weights, item explanations, scoring criteria, and an operations manual. Exploratory traditional psychometric analyses showed limited internal consistency and poor structural fit, consistent with the formative/composite nature of the tool and should not be interpreted as evidence that all items measure a single latent trait. Conclusions: CMICT‐RQIT V1.0 can assist researchers in selecting research topics, with its greatest value lying in providing a concise summary of the importance of research question along with a comprehensive 24‐item checklist for clinical investigators. At the same time, it offers reviewers transparent criteria for assessing the importance of research questions, thereby promoting the objectivity and fairness of evaluations. CMICT‐RQIT V1.0 should be used primarily as a structured checklist and decision‐support index.
- 30 June 2026
- Published by Wiley in Journal of Evidence-Based Medicine
- Vol. 19 (2) , e70156
Open AccessDevelopment and Preliminary Validation of the Chinese Medicine Interventional Clinical Trials Research Question Importance Tool (CMICT‐RQIT)
Objective: Evidence‐based medicine emphasizes clinical research driven by important questions, yet Chinese medicine lacks practical quantitative tools to identify such questions. We developed the Chinese Medicine Interventional Clinical Trials Research Question Importance Tool (CMICT‐RQIT) to support topic selection and provide transparent criteria for proposal review, promoting high‐quality clinical research in Chinese medicine. Methods: This study followed internationally accepted procedures of conceptualization and operationalization. Using a mixed‐methods approach—including a literature review, qualitative interviews, Delphi surveys, expert consensus meetings, and the analytic hierarchy process—we developed the CMICT‐RQIT. CMICT‐RQIT was prespecified and interpreted as a formative/composite multicriteria decision‐support tool. Results: Following a standardized development process comprising three stages—framework construction, tool development, and tool evaluation—the CMICT‐RQIT V1.0 was established. It consists of four domains, 10 facets, and 24 items, each with corresponding composite weights, item explanations, scoring criteria, and an operations manual. Exploratory traditional psychometric analyses showed limited internal consistency and poor structural fit, consistent with the formative/composite nature of the tool and should not be interpreted as evidence that all items measure a single latent trait. Conclusions: CMICT‐RQIT V1.0 can assist researchers in selecting research topics, with its greatest value lying in providing a concise summary of the importance of research question along with a comprehensive 24‐item checklist for clinical investigators. At the same time, it offers reviewers transparent criteria for assessing the importance of research questions, thereby promoting the objectivity and fairness of evaluations. CMICT‐RQIT V1.0 should be used primarily as a structured checklist and decision‐support index.
- Top Cited Papers
- 23 January 2026
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 24 (2) , 201-209
Developing a core outcome set for clinical research on Chinese medicine dampness syndrome
- 23 January 2026
- Published by Elsevier in Journal of Integrative Medicine
- Vol. 24 (2) , 201-209
Top Cited PapersDeveloping a core outcome set for clinical research on Chinese medicine dampness syndrome
- Open Access
Xuefu Zhuyu Oral Liquid as Adjunctive Therapy on Stable Angina: A Randomized Clinical Trial
Background: Stable angina (SA) is a leading cause of disability worldwide, and there is increasing interest in nonpharmacological treatments. Xuefu Zhuyu oral liquid (XZOL) is a Chinese medicine that has been approved in China for the treatment of SA, but further studies are needed to establish its efficacy and safety. We aimed to provide a reliable assessment of the safety and efficacy of XZOL in patients with SA. Methods: We did a multi-centre, randomised, double-blind, placebo-controlled trial at 6 hospitals in China. Participants were randomized into 2 treatment groups, and allocated to receive of either XZOL or matching placebo over 12 weeks and were followed-up for 12 weeks. The primary efficacy outcome was the average pain intensity of angina, which was measured by the change from baseline to week 12 on a 10-cm visual analogue scale. Results: Of 263 patients screened, 148 participants were randomly assigned with primary outcome data in the ITT (intention-to-treat) population (74 in the XZOL group and 74 in the placebo group), and 99 participants in the PP (per-protocol) population (48 in the XZOL group and 51 in the placebo group). Mean change in VAS at week 12 were −2.27 in the XZOL group and −1.85 in the placebo group (difference - 0.52, 95% CI −0.99 to −0.05; P = 0.029) among the ITT population, and −2.54 in the XZOL group and −1.79 in the placebo group (difference −0.81, 95% CI −1.40 to −0.22; P = 0.007) among the PP population. The neutral results were shown in adjusted and sensitivity analyses. There was no significant difference in adverse events. Conclusion: This randomised, placebo-controlled, double-blind, clinical trial showed XZOL was associated with a significantly greater reduction in the levels of pain intensity of angina over 12 weeks and was superior to placebo in alleviating SA.
Open AccessXuefu Zhuyu Oral Liquid as Adjunctive Therapy on Stable Angina: A Randomized Clinical Trial
Background: Stable angina (SA) is a leading cause of disability worldwide, and there is increasing interest in nonpharmacological treatments. Xuefu Zhuyu oral liquid (XZOL) is a Chinese medicine that has been approved in China for the treatment of SA, but further studies are needed to establish its efficacy and safety. We aimed to provide a reliable assessment of the safety and efficacy of XZOL in patients with SA. Methods: We did a multi-centre, randomised, double-blind, placebo-controlled trial at 6 hospitals in China. Participants were randomized into 2 treatment groups, and allocated to receive of either XZOL or matching placebo over 12 weeks and were followed-up for 12 weeks. The primary efficacy outcome was the average pain intensity of angina, which was measured by the change from baseline to week 12 on a 10-cm visual analogue scale. Results: Of 263 patients screened, 148 participants were randomly assigned with primary outcome data in the ITT (intention-to-treat) population (74 in the XZOL group and 74 in the placebo group), and 99 participants in the PP (per-protocol) population (48 in the XZOL group and 51 in the placebo group). Mean change in VAS at week 12 were −2.27 in the XZOL group and −1.85 in the placebo group (difference - 0.52, 95% CI −0.99 to −0.05; P = 0.029) among the ITT population, and −2.54 in the XZOL group and −1.79 in the placebo group (difference −0.81, 95% CI −1.40 to −0.22; P = 0.007) among the PP population. The neutral results were shown in adjusted and sensitivity analyses. There was no significant difference in adverse events. Conclusion: This randomised, placebo-controlled, double-blind, clinical trial showed XZOL was associated with a significantly greater reduction in the levels of pain intensity of angina over 12 weeks and was superior to placebo in alleviating SA.
- 4 October 2024
- Published by Elsevier in Phytomedicine
- Vol. 135, 156112
Effect of Xuefu zhuyu oral liquid on tension-type headache: A randomized clinical trial
- 4 October 2024
- Published by Elsevier in Phytomedicine
- Vol. 135, 156112
Effect of Xuefu zhuyu oral liquid on tension-type headache: A randomized clinical trial
- Open Access
- 28 November 2023
- Published by Elsevier in European Journal of Integrative Medicine
- Vol. 66
Outcomes for clinical research on Chinese medicine dampness syndrome: A protocol of developing a core outcome set
- 28 November 2023
- Published by Elsevier in European Journal of Integrative Medicine
- Vol. 66
Open AccessOutcomes for clinical research on Chinese medicine dampness syndrome: A protocol of developing a core outcome set
- Open Access
- 13 October 2023
- Published by Springer Nature in Research Square
Optimizing a Interpretable Diagnostic Model for Colorectal Cancer Based on Yin Deficiency Pattern Characteristic Genes Using 21 Machine Learning Algorithms and Bayesian Opitimization
In this study, we aimed to identify a core set of Yin Deficiency Pattern (YDP) genes for predicting colorectal cancer (CRC) and to construct reliable machine learning models optimized by Optuna. Comprehensive analysis was performed on nine datasets, totaling 1,680 samples. A CRC diagnostic prediction model was developed by comparing 21 machine learning classification models with Optuna hyperparameter optimization and validated across six independent external cohorts. Additionally, the expression patterns of the core diagnostic genes were experimentally validated. Linear Discriminant Analysis (LDA), along with four other machine learning models (please specify these models), ranked as the top five performing models across six cohorts, demonstrating superior performance with AUC values exceeding 0.99 and all other performance metrics surpassing 0.899. This study marks the first utilization of four specific novel machine learning models (again, please specify these models) in CRC diagnosis. The robust performance of the top models across multiple external validation sets underscores the reliability and generalizability of our diagnostic model. These results hold potential implications for the development of personalized medicine approaches in CRC treatment, offering a new avenue for early detection and prognosis improvement.
- 13 October 2023
- Published by Springer Nature in Research Square
Open AccessOptimizing a Interpretable Diagnostic Model for Colorectal Cancer Based on Yin Deficiency Pattern Characteristic Genes Using 21 Machine Learning Algorithms and Bayesian Opitimization
In this study, we aimed to identify a core set of Yin Deficiency Pattern (YDP) genes for predicting colorectal cancer (CRC) and to construct reliable machine learning models optimized by Optuna. Comprehensive analysis was performed on nine datasets, totaling 1,680 samples. A CRC diagnostic prediction model was developed by comparing 21 machine learning classification models with Optuna hyperparameter optimization and validated across six independent external cohorts. Additionally, the expression patterns of the core diagnostic genes were experimentally validated. Linear Discriminant Analysis (LDA), along with four other machine learning models (please specify these models), ranked as the top five performing models across six cohorts, demonstrating superior performance with AUC values exceeding 0.99 and all other performance metrics surpassing 0.899. This study marks the first utilization of four specific novel machine learning models (again, please specify these models) in CRC diagnosis. The robust performance of the top models across multiple external validation sets underscores the reliability and generalizability of our diagnostic model. These results hold potential implications for the development of personalized medicine approaches in CRC treatment, offering a new avenue for early detection and prognosis improvement.
- Open Access
- 10 June 2021
- Published by Hindawi Limited in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-9
Outcome Reporting Variability in Trials of Chinese Medicine for Hyperlipidemia: A Systematic Review for Developing a Core Outcome Set
Outcome Reporting Variability in Trials of Chinese Medicine for Hyperlipidemia: A Systematic Review for Developing a Core Outcome Set: Introduction. Hyperlipidemia is an underlying process behind cardiovascular disease. Chinese medicine (CM) may be effective in treating hyperlipidemia, but there is a lack of studies with high methodological quality. A major reason for this is heterogeneity in outcome reporting. Therefore, this study explores the degree of outcome reporting variation in CM trials for hyperlipidemia. It then generates a list of potentially important outcomes for developing a core outcome set (COS). Methods. A systematic review of literature focusing on studies of CM for hyperlipidemia was conducted. Outcomes were listed verbatim and grouped into 8 domains. Outcome frequency and definition uniformity were analyzed. Results. 3,702 studies and 452 individual outcomes were identified. These outcomes were reported 27,328 times, of which 1.6 were reported as primary outcomes, and 13.3 were defined. The most frequent outcome was total triglyceride, represented in 86.7 of the studies, followed by total cholesterol (86.0), total effective rate (75.1), high-density lipoprotein cholesterol (73.2), and low-density lipoprotein cholesterol (60.5). However, 43.6 of outcomes were reported only once. The largest outcome domain was pathological or pathophysiological outcomes, which included 67.0 of outcomes. Of the response rate related outcomes domain, total effective rate was the most frequently reported outcome (n=2,780), and 95.3 of the studies gave a clear definition. However, these definitions were often contradictory. Only 10 papers reported cardiovascular events, 3 of which referred to them as primary outcomes. Moreover, ten patient-reported outcomes were reported in the retrieved literature 19 times in total. The majority of the outcomes did not report measurement instruments (MIs) (269/453, 59.4). MIs of the surrogate outcomes were reported more frequently. Conclusion. Outcome reporting in CM trials for hyperlipidemia is inconsistent and ill-defined, creating barriers to data synthesis and comparison. Thus, we propose and are developing a COS for CM trials for hyperlipidemia.
- 10 June 2021
- Published by Hindawi Limited in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-9
Open AccessOutcome Reporting Variability in Trials of Chinese Medicine for Hyperlipidemia: A Systematic Review for Developing a Core Outcome Set
Outcome Reporting Variability in Trials of Chinese Medicine for Hyperlipidemia: A Systematic Review for Developing a Core Outcome Set: Introduction. Hyperlipidemia is an underlying process behind cardiovascular disease. Chinese medicine (CM) may be effective in treating hyperlipidemia, but there is a lack of studies with high methodological quality. A major reason for this is heterogeneity in outcome reporting. Therefore, this study explores the degree of outcome reporting variation in CM trials for hyperlipidemia. It then generates a list of potentially important outcomes for developing a core outcome set (COS). Methods. A systematic review of literature focusing on studies of CM for hyperlipidemia was conducted. Outcomes were listed verbatim and grouped into 8 domains. Outcome frequency and definition uniformity were analyzed. Results. 3,702 studies and 452 individual outcomes were identified. These outcomes were reported 27,328 times, of which 1.6 were reported as primary outcomes, and 13.3 were defined. The most frequent outcome was total triglyceride, represented in 86.7 of the studies, followed by total cholesterol (86.0), total effective rate (75.1), high-density lipoprotein cholesterol (73.2), and low-density lipoprotein cholesterol (60.5). However, 43.6 of outcomes were reported only once. The largest outcome domain was pathological or pathophysiological outcomes, which included 67.0 of outcomes. Of the response rate related outcomes domain, total effective rate was the most frequently reported outcome (n=2,780), and 95.3 of the studies gave a clear definition. However, these definitions were often contradictory. Only 10 papers reported cardiovascular events, 3 of which referred to them as primary outcomes. Moreover, ten patient-reported outcomes were reported in the retrieved literature 19 times in total. The majority of the outcomes did not report measurement instruments (MIs) (269/453, 59.4). MIs of the surrogate outcomes were reported more frequently. Conclusion. Outcome reporting in CM trials for hyperlipidemia is inconsistent and ill-defined, creating barriers to data synthesis and comparison. Thus, we propose and are developing a COS for CM trials for hyperlipidemia.
- Open Access
- 7 January 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-7
A core outcome set for clinical trials of Chinese medicine for hyperlipidemia: a study protocol for a systematic review and a Delphi survey
Hyperlipidemia, defined as elevated lipid levels, is the primary and major risk factor for atherosclerotic cardiovascular disease. Several studies have evaluated the effects of Chinese medicine (CM) on hyperlipidemia. However, due to the varied designs and methods of these studies, data synthesis has been difficult, restricting the practical value of the findings. Developing a core outcome set (COS) could solve these methodological concerns. In this paper, we report a protocol to develop a COS for CM clinical trials for hyperlipidemia (COS-CM-Hyperlipidemia). The development of COS-CM-Hyperlipidemia will include four stages: (1) a systematic review to identify potential important outcomes—a study advisory group, composed of core stakeholders of hyperlipidemia, will be set up afterwards to evaluate the identified outcomes and a candidate outcome set will be developed accordingly; (2) a panel of experts will be invited to conduct a three-round Delphi survey, so that the experts’ opinions on the importance of outcomes for treating hyperlipidemia with CM will be collected; (3) a consensus meeting with clinicians, patients, and other key stakeholders will be conducted to finalize the items and definitions; and (4) COS-CM-Hyperlipidemia will be promoted and updated. The development of this COS will improve the design and operation of CM trials on hyperlipidemia, keeping them in compliance with international standards, as well as the comparability and utility of their results. The Core Outcome Measures in Effectiveness Trials Initiative (COMET): http://www.comet-initiative.org/studies/details/983 . Registered on 25 April 2017.
- 7 January 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-7
Open AccessA core outcome set for clinical trials of Chinese medicine for hyperlipidemia: a study protocol for a systematic review and a Delphi survey
Hyperlipidemia, defined as elevated lipid levels, is the primary and major risk factor for atherosclerotic cardiovascular disease. Several studies have evaluated the effects of Chinese medicine (CM) on hyperlipidemia. However, due to the varied designs and methods of these studies, data synthesis has been difficult, restricting the practical value of the findings. Developing a core outcome set (COS) could solve these methodological concerns. In this paper, we report a protocol to develop a COS for CM clinical trials for hyperlipidemia (COS-CM-Hyperlipidemia). The development of COS-CM-Hyperlipidemia will include four stages: (1) a systematic review to identify potential important outcomes—a study advisory group, composed of core stakeholders of hyperlipidemia, will be set up afterwards to evaluate the identified outcomes and a candidate outcome set will be developed accordingly; (2) a panel of experts will be invited to conduct a three-round Delphi survey, so that the experts’ opinions on the importance of outcomes for treating hyperlipidemia with CM will be collected; (3) a consensus meeting with clinicians, patients, and other key stakeholders will be conducted to finalize the items and definitions; and (4) COS-CM-Hyperlipidemia will be promoted and updated. The development of this COS will improve the design and operation of CM trials on hyperlipidemia, keeping them in compliance with international standards, as well as the comparability and utility of their results. The Core Outcome Measures in Effectiveness Trials Initiative (COMET): http://www.comet-initiative.org/studies/details/983 . Registered on 25 April 2017.